Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
DOJ Sues Virginia Over Failure to Provide Full Voter Registration Records 
South Korea Inflation Hits Five-Month Low as CPI Reaches Central Bank Target 
Supreme Court Tests Federal Reserve Independence Amid Trump’s Bid to Fire Lisa Cook 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
Asian Currencies Strengthen as Indian Rupee and Australian Dollar Rally 
Oil Prices Steady as Markets Weigh U.S.-Iran Talks, Dollar Strength Caps Gains 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
DOJ Urges Judge to Block Lawmakers’ Bid for Special Master in Jeffrey Epstein Records Case 
Former South Korean President Yoon Suk Yeol Faces Historic Court Ruling Over Failed Martial Law Attempt 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
